ClinicalTrials.gg
CompletedNCT02624869HAUSER-OLEUpdated May 29, 2024Results posted

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

A Phase 3 interventional study of Evolocumab in Familial Hypercholesterolemia, sponsored by Amgen. Completed at 46 sites in 23 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Primary conditionHomozygous Familial HypercholesterolemiaRegistry: Hyperlipoproteinemia Type IIReclassifiedWhy we changed it
Registry
Hyperlipoproteinemia Type II — the first condition term the registry derived for this study.
ClinicalTrials.gg
Homozygous Familial Hypercholesterolemia
Why
  1. The study's title name Homozygous Familial Hypercholesterolemia, a narrower term within Hyperlipoproteinemia Type II.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy — 2 open to participants now, 3 under way, 1 of them phase 3. Homozygous Familial Hypercholesterolemia · Italy.

Enrollment
3rd of 12
163 · median 62
Started
2016
with 1 other
Phase 3
8 of 15
1 open now
Registered
7th of 15
by date
Lead sponsor
3 of 15
Amgen

Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2016, is one of 8 in phase 3, and was the 7th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

2 of the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, or all of them as a file.
02

Study summary

The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.

03

Conditions studied

  • Familial Hypercholesterolemia

Keywords

  • Hypercholesterolemia
  • Elevated Cholesterol
  • High Cholesterol
  • PCSK9 mutations
  • Severe Familial Hypercholesterolemia
  • evolocumab
  • Repatha
  • Heterozygous Familial Hypercholesterolemia
  • Homozygous Familial Hypercholesterolemia
  • Pediatric
  • Paediatric
04

In context

Homozygous Familial Hypercholesterolemia Reclassified

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

This study's enrollment of 163 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.

Browse Homozygous Familial Hypercholesterolemia studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Homozygous Familial Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipoproteinemia Type II. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Heterozygous Familial Hypercholesterolemia (HeFH):

-Completed Study 20120123 (NCT02392559) while still on assigned product and did not experience a treatment-related serious adverse event

Homozygous Familial Hypercholesterolemia (HoFH):

  • Male or female, ≥ 10 to ≤ 17 years of age at time of enrollment
  • Diagnosis of HoFH
  • On a low-fat diet and receiving background lipid-lowering therapy
  • Lipid-lowering therapy unchanged for ≥ 4 weeks prior to LDL-C screening; fibrates must be stable for at least 6 weeks prior to screening.
  • Fasting LDL-C at screening ≥ 130 mg/dL (3.4 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion criteria

Exclusion Criteria:

-Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s); except Study 20120123

HoFH:

  • Moderate to severe renal dysfunction
  • Active liver disease or hepatic dysfunction,
  • Creatine kinase > 3 times the (ULN) at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: Repatha®, AMG 145

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event is defined as any untoward medical occurrence in a clinical trial participant, not necessarily having a causal relationship with study treatment. A serious AE is as an AE that met at least 1 of the following criteria: * fatal; * life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. AEs were graded for severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.

    Time frame: From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.

Secondary outcomes

  1. Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants

    For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

    Time frame: Baseline and week 80

  2. Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  3. Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants

    For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

    Time frame: Baseline and week 80

  4. Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  5. Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

    Time frame: Baseline and week 80

  6. Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  7. Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

    Time frame: Baseline and week 80

  8. Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  9. Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

    Time frame: Baseline and week 80

  10. Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  11. Change From Baseline to Week 80 in LDL-C in HeFH Participants

    For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

    Time frame: Baseline and week 80

  12. Change From Baseline to Week 80 in LDL-C in HoFH Participants

    For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  13. Change From Baseline to Week 80 in Estradiol Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  14. Change From Baseline to Week 80 in Testosterone Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  15. Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  16. Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  17. Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  18. Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  19. Change From Baseline to Week 80 in Cortisol Levels

    For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

    Time frame: Baseline and week 80

  20. Number of Participants With Liver Function Test Abnormalities at Week 80

    Liver function tests included alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels and total bilirubin levels.

    Time frame: Week 80

  21. Number of Participants With Abnormalities in Levels of Creatine Kinase (CK) at Week 80

    The number of participants with levels of creatine kinase greater than 5 times the upper limit of normal (ULN) and greater than 10 times the ULN, measured by the central laboratory.

    Time frame: Week 80

  22. Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)

    Carotid intima-media thickness measures the thickness of the intima and media, the inner two layers of the carotid artery, and is used to determine the extent of plaque buildup in the walls of the arteries (atherosclerosis) supplying blood to the head. CIMT was measured by ultrasonography and analyzed at a core laboratory. The largest values measured in the left common carotid artery (LCCA) and the right common carotid artery (RCCA) are averaged in this analysis.

    Time frame: Baseline and week 80

  23. Change From Baseline in Height at Weeks 24, 48, and 80

    Time frame: Baseline and weeks 24, 48, and 80

  24. Change From Baseline in Weight at Weeks 24, 48, and 80

    Time frame: Baseline and weeks 24, 48, and 80

  25. Number of Participants With Change in Tanner Staging From Baseline to Week 80

    Pubertal growth and sexual maturity was assessed separately for males and females using the 5 Tanner stages where stage 1 = prepubertal and stage 5 = mature. The number of participants with any change in Tanner Stage from baseline is reported.

    Time frame: Baseline and week 80

08

Results

Posted Jan 14, 2022

Participant flow

This study was conducted at 46 centers in 23 countries (Australia, Austria, Belgium, Brazil, Canada, Colombia, Czech Republic, Greece, Hungary, Italy, Malaysia, Netherlands, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Turkey, United Kingdom, and United States of America).

Participant flow — Overall Study
MilestoneHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Started4910113
Received study drug4910112
Completed489811
Not completed132
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject131

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event is defined as any untoward medical occurrence in a clinical trial participant, not necessarily having a causal relationship with study treatment. A serious AE is as an AE that met at least 1 of the following criteria: * fatal; * life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. AEs were graded for severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.

Time frame:
From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Any treatment-emergent adverse event (TEAE)36697
TEAE ≥ Grade 225565
TEAE ≥ Grade 3422
TEAE ≥ Grade 4010
Serious adverse events222
TEAE leading to discontinuation of evolocumab000
Fatal adverse events000
SecondaryPercent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants

For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · percent change
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants
percent changeHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants-36.01 ± 4.28-34.96 ± 3.05
SecondaryPercent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · percent change
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants
percent changeHoFH: Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants-14.29 (-40.61 to 3.54)
SecondaryPercent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants

For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · percent change
Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants
percent changeHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants-32.37 ± 3.96-31.95 ± 2.89
SecondaryPercent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · percent change
Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants
percent changeHoFH: Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants-13.03 (-40.68 to 2.69)
SecondaryPercent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants

For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · percent change
Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants
percent changeHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants-27.10 ± 3.32-24.15 ± 2.99
SecondaryPercent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · percent change
Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants
percent changeHoFH: Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants-19.17 (-33.33 to 11.59)
SecondaryPercent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants

For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · percent change
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants
percent changeHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants-28.78 ± 3.48-28.32 ± 2.47
SecondaryPercent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · percent change
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants
percent changeHoFH: Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants3.71 (-41.17 to 7.57)
SecondaryPercent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants

For HeFH participants baseline was defined as the baseline value in the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · percent change
Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants
percent changeHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants-31.00 ± 3.66-29.89 ± 2.80
SecondaryPercent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · percent change
Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants
percent changeHoFH: Evolocumab 420 mg QM
Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants-2.96 (-35.71 to 9.30)
SecondaryChange From Baseline to Week 80 in LDL-C in HeFH Participants

For HeFH participants baseline was defined as the baseline value of the parent study 20120123.

Time frame:
Baseline and week 80
Reported as:
Mean · mg/dL
Change From Baseline to Week 80 in LDL-C in HeFH Participants
mg/dLHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM
Change From Baseline to Week 80 in LDL-C in HeFH Participants-67.2 ± 8.2-63.1 ± 5.6
SecondaryChange From Baseline to Week 80 in LDL-C in HoFH Participants

For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Median · mg/dL
Change From Baseline to Week 80 in LDL-C in HoFH Participants
mg/dLHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in LDL-C in HoFH Participants-36.5 (-180.5 to 16.0)
SecondaryChange From Baseline to Week 80 in Estradiol Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · pmol/L
Change From Baseline to Week 80 in Estradiol Levels
pmol/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Estradiol Levels131.3 ± 45.348.2 ± 58.1283.0 ± 130.0
SecondaryChange From Baseline to Week 80 in Testosterone Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · nmol/L
Change From Baseline to Week 80 in Testosterone Levels
nmol/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Testosterone Levels5.282 ± 1.5673.230 ± 1.1672.916 ± 0.984
SecondaryChange From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · IU/L
Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels
IU/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels1.88 ± 0.900.60 ± 0.371.18 ± 0.35
SecondaryChange From Baseline to Week 80 in Luteinizing Hormone (LH) Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · IU/L
Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels
IU/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels2.88 ± 1.511.04 ± 0.951.76 ± 0.84
SecondaryChange From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · pmol/L
Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels
pmol/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels0.78 ± 0.550.55 ± 0.61-0.75 ± 1.79
SecondaryChange From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · μmol/L
Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels
μmol/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels1.051 ± 0.2220.956 ± 0.1260.944 ± 0.247
SecondaryChange From Baseline to Week 80 in Cortisol Levels

For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).

Time frame:
Baseline and week 80
Reported as:
Mean · nmol/L
Change From Baseline to Week 80 in Cortisol Levels
nmol/LHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Cortisol Levels29.81 ± 28.3451.18 ± 25.1957.26 ± 56.11
SecondaryNumber of Participants With Liver Function Test Abnormalities at Week 80

Liver function tests included alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels and total bilirubin levels.

Time frame:
Week 80
Reported as:
Count of participants · Participants
Number of Participants With Liver Function Test Abnormalities at Week 80
ParticipantsHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
ALT or AST > 3 x ULN000
ALT or AST > 5 x ULN000
Total bilirubin > 2 x ULN021
SecondaryNumber of Participants With Abnormalities in Levels of Creatine Kinase (CK) at Week 80

The number of participants with levels of creatine kinase greater than 5 times the upper limit of normal (ULN) and greater than 10 times the ULN, measured by the central laboratory.

Time frame:
Week 80
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Levels of Creatine Kinase (CK) at Week 80
ParticipantsHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
CK > 5 x ULN001
CK > 10 x ULN000
SecondaryChange From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)

Carotid intima-media thickness measures the thickness of the intima and media, the inner two layers of the carotid artery, and is used to determine the extent of plaque buildup in the walls of the arteries (atherosclerosis) supplying blood to the head. CIMT was measured by ultrasonography and analyzed at a core laboratory. The largest values measured in the left common carotid artery (LCCA) and the right common carotid artery (RCCA) are averaged in this analysis.

Time frame:
Baseline and week 80
Reported as:
Mean · mm
Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)
mmHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)-0.019 ± 0.007-0.012 ± 0.0060.006 ± 0.032
SecondaryChange From Baseline in Height at Weeks 24, 48, and 80
Time frame:
Baseline and weeks 24, 48, and 80
Reported as:
Mean · cm
Change From Baseline in Height at Weeks 24, 48, and 80
cmHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Females: Baseline158.1 ± 2.3157.9 ± 1.3149.4 ± 7.1
Females: Change at week 242.8 ± 0.72.0 ± 0.41.6 ± 1.1
Females: Change at week 484.2 ± 1.02.8 ± 0.51.4 ± 2.4
Females: Change at week 804.0 ± 1.73.4 ± 0.72.4 ± 3.9
Males: Baseline158.2 ± 3.0163.7 ± 1.9158.9 ± 4.8
Males: Change at week 243.4 ± 0.53.8 ± 0.53.8 ± 0.8
Males: Change at week 486.2 ± 0.86.2 ± 0.75.3 ± 1.2
Males: Change at week 809.3 ± 1.59.0 ± 1.19.2 ± 1.6
SecondaryChange From Baseline in Weight at Weeks 24, 48, and 80
Time frame:
Baseline and weeks 24, 48, and 80
Reported as:
Mean · kg
Change From Baseline in Weight at Weeks 24, 48, and 80
kgHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Females: Baseline52.8 ± 2.957.0 ± 2.042.7 ± 1.3
Females: Change at week 243.3 ± 0.82.3 ± 0.63.4 ± 2.1
Females: Change at week 484.3 ± 1.13.5 ± 0.74.7 ± 5.3
Females: Change at week 805.6 ± 1.35.2 ± 0.85.5 ± 4.2
Males: Baseline54.1 ± 3.661.0 ± 3.251.7 ± 4.9
Males: Change at week 244.4 ± 0.94.6 ± 0.74.6 ± 0.9
Males: Change at week 486.8 ± 1.37.4 ± 1.07.6 ± 1.2
Males: Change at week 8010.9 ± 1.611.2 ± 1.410.6 ± 2.3
SecondaryNumber of Participants With Change in Tanner Staging From Baseline to Week 80

Pubertal growth and sexual maturity was assessed separately for males and females using the 5 Tanner stages where stage 1 = prepubertal and stage 5 = mature. The number of participants with any change in Tanner Stage from baseline is reported.

Time frame:
Baseline and week 80
Reported as:
Count of participants · Participants
Number of Participants With Change in Tanner Staging From Baseline to Week 80
ParticipantsHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
Males: Staging by genital size13206
Males: Staging by pubic hair14216
Females: Staging by breast development11271
Females: Staging by pubic hair11261

Adverse events

Collected over From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HeFH (Placebo in Parent Study): Evolocumab 420 mg QM0/49 (0%)2/49 (4.1%)27/49 (55.1%)
HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM0/101 (0%)2/101 (2%)45/101 (44.6%)
HoFH: Evolocumab 420 mg QM0/13 (0%)2/12 (16.7%)7/12 (58.3%)
Most frequent serious events
Most frequent serious events
EventHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
AppendicitisInfections and infestations0/490/1011/12
Arteriovenous fistula aneurysmInjury, poisoning and procedural complications0/490/1011/12
Appendicitis perforatedInfections and infestations1/490/1010/12
PeritonitisInfections and infestations1/490/1010/12
Wrist fractureInjury, poisoning and procedural complications1/490/1010/12
HeadacheNervous system disorders0/491/1010/12
Anorexia nervosaPsychiatric disorders0/491/1010/12
Most frequent other events
Showing 10 of 22
Most frequent other events
EventHeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QM
EpistaxisRespiratory, thoracic and mediastinal disorders0/491/1012/12
NasopharyngitisInfections and infestations8/4914/1010/12
Influenza like illnessGeneral disorders5/498/1010/12
PyrexiaGeneral disorders5/491/1010/12
HeadacheNervous system disorders4/499/1011/12
Abdominal pain upperGastrointestinal disorders1/495/1011/12
NauseaGastrointestinal disorders0/491/1011/12
Injection site haemorrhageGeneral disorders0/491/1011/12
InfluenzaInfections and infestations0/493/1011/12
Otitis mediaInfections and infestations0/491/1011/12

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
Mean13.8 ± 2.514.2 ± 2.412.4 ± 2.014.0 ± 2.5
Age, Customized
Age, Customized(Participants)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
2 - 11 years1118635
12 - 17 years37767120
18 - 64 years1708
Sex: Female, Male
Sex: Female, Male(Participants)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
Female2459285
Male25421178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
Hispanic or Latino76013
Not Hispanic or Latino429513150
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
American Indian or Alaska Native0000
Asian0224
Black or African American0202
Native Hawaiian or Other Pacific Islander0000
White40869135
Other911222
Region
Region(Participants)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
North America812020
Europe33657105
Latin America818026
Asia Pacific06612
Low-density Lipoprotein Cholesterol (LDL-C) Concentration
Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
Mean184.0 ± 48.3184.4 ± 45.2426.0 ± 166.4202.2 ± 88.8
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration(mg/dL)HeFH (Placebo in Parent Study): Evolocumab 420 mg QMHeFH (Evolocumab in Parent Study): Evolocumab 420 mg QMHoFH: Evolocumab 420 mg QMTotal
Mean201.0 ± 49.3203.4 ± 47.5443.7 ± 170.8220.5 ± 90.2

3 further baseline measures are reported on the registry.

09

Study locations

46 sites
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Nashville, Tennessee 37212, United States
  • Research Site
    Camperdown, New South Wales 2050, Australia
  • Research Site
    Feldkirch, 6800, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    La Louvière, 7100, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Fortaleza, Ceará 60430-270, Brazil
  • Research Site
    Brasília, Distrito Federal 71625-175, Brazil
  • Research Site
    São Paulo, 04040-000, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Quebec, G1V 4W2, Canada
  • Research Site
    Barranquilla, Atlántico 080020, Colombia
  • Research Site
    Bucaramanga, Santander 81004, Colombia
  • Research Site
    Svitavy, 568 25, Czechia
  • Research Site
    Athens, 17674, Greece
  • Research Site
    Thessaloniki, 54642, Greece
  • Research Site
    Budapest, 1094, Hungary
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Kota Bharu, Kelantan 16150, Malaysia
  • Research Site
    Amsterdam, 1066 EC, Netherlands
  • Research Site
    Bergen, 5021, Norway
  • Research Site
    Oslo, 0586, Norway
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Guimaraes, 4835-044, Portugal
  • Research Site
    Saint Petersburg, 191025, Russian Federation
  • Research Site
    Ljubljana, 1000, Slovenia
  • Research Site
    Parktown, Gauteng 2193, South Africa
  • Research Site
    Parow, Western Cape 7505, South Africa
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    A Coruña, Galicia 15001, Spain
  • Research Site
    Lugo, Galicia 27003, Spain
  • Research Site
    Geneva 14, 1211, Switzerland
  • Research Site
    Reinach, 4153, Switzerland
  • Research Site
    Ankara, 06500, Turkey
  • Research Site
    Izmir, 35100, Turkey
  • Research Site
    Birmingham, B4 6NH, United Kingdom
10

References and documents

Publications

  • Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, Bergeron J, Wang B, Bartuli A, Buonuomo PS, Greber-Platzer S, Luirink I, Bhatia AK, Raal FJ, Kastelein JJP, Wiegman A, Gaudet D. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 Oct;10(10):732-740. doi: 10.1016/S2213-8587(22)00221-2. Epub 2022 Sep 5. PubMed 36075246 ↗
  • Raal FJ, Hegele RA, Ruzza A, Lopez JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May;44(5):1156-1164. doi: 10.1161/ATVBAHA.123.320268. Epub 2024 Mar 28. PubMed 38545781 ↗
  • Santos RD, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, St Pierre J, Kastelein JJP, Hovingh GK, Wiegman A, Gaudet D, Raal FJ. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15;31(3):302-310. doi: 10.1093/eurjpc/zwad332. PubMed 37855448 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2021, 56 months.

Results were first posted in Jan 2022, 7 months after primary completion.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2015
First posted
Dec 9, 2015
StartActual
Sep 10, 2016
Primary completionActual
Jun 1, 2021
CompletionActual
Jun 1, 2021
Results first posted
Jan 14, 2022
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02624869
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 9, 2015
Start date
Sep 10, 2016
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021
Results posted
Jan 14, 2022
Last update
May 29, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion